Form 4: Verona Pharma CFO Mark Hahn Reports Share Transaction

Mark Hahn, CFO of Verona Pharma plc, reports a transaction involving ordinary shares to cover tax obligations related to vesting restricted share units.

Summary

• On August 1, 2024, Mark Hahn, the Chief Financial Officer of Verona Pharma plc, reported a transaction involving the company's ordinary shares.
• The transaction involved the withholding of 88,544 ordinary shares to satisfy tax obligations related to the vesting of previously reported Restricted Share Units.
• The price per share was $2.8325, based on the closing price of the Issuer's American Depositary Shares (ADSs) on the Nasdaq Stock Market LLC on July 31, 2024, divided by eight.
• Following the transaction, Hahn beneficially owns 14,854,488 ordinary shares, including those underlying Restricted Share Units and ADSs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and tax obligations, common in publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, as mandated by the SEC.
• The transaction is typical of executives managing their equity compensation and related tax liabilities.
• Comparable companies in the pharmaceutical sector also regularly disclose similar transactions by their executives.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, as it relates to tax obligations of an executive.
• The transaction does not directly affect employees, customers, suppliers, or creditors.

Key Dates